NASDAQ · NBIX
Neurocrine Biosciences, Inc.
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
Loading market information…
NASDAQ · DNLI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Denali Therapeutics Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Denali Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$0.78-9.86% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.67+10.67% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.63-5.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $34.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$28.68+$0.61 (+2.17%)
Amylyx Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.29% below the high.
$16.49+$0.97 (+6.25%)
Biohaven Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.2% below the high.
$24.21+$1.71 (+7.6%)
Rapport Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 54.26% below the high.
$2.24-$0.01 (-0.44%)
Alector, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.84% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
